Similar articles

• HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.

  Batra L, Verma SK, Nagar DP, Saxena N, Pathak P, Pant SC, Tuteja U. Batra L, et al. PLoS Negl Trop Dis. 2014 Dec 4;8(12):e3322. doi: 10.1371/journal.pntd.0003322. eCollection 2014 Dec. PLoS Negl Trop Dis. 2014. Retraction in: PLoS Negl Trop Dis. 2024 Aug 9;18(8):e0012406. doi: 10.1371/journal.pntd.0012406. PMID: 25474358 Free PMC article. Retracted.
• A Recombinant Trivalent Fusion Protein F1-LcrV-HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis.

  Verma SK, Batra L, Tuteja U. Verma SK, et al. Front Microbiol. 2016 Jul 5;7:1053. doi: 10.3389/fmicb.2016.01053. eCollection 2016. Front Microbiol. 2016. PMID: 27458447 Free PMC article.
• Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.

  Gupta A, Narayan B, Kumar S, Verma SK. Gupta A, et al. Front Immunol. 2020 Jun 12;11:988. doi: 10.3389/fimmu.2020.00988. eCollection 2020. Front Immunol. 2020. PMID: 32595634 Free PMC article.
• Plague vaccines and the molecular basis of immunity against Yersinia pestis.

  Quenee LE, Schneewind O. Quenee LE, et al. Hum Vaccin. 2009 Dec;5(12):817-23. doi: 10.4161/hv.9866. Epub 2009 Dec 1. Hum Vaccin. 2009. PMID: 19786842 Review.
• Protective immunity against plague.

  Cornelius C, Quenee L, Anderson D, Schneewind O. Cornelius C, et al. Adv Exp Med Biol. 2007;603:415-24. doi: 10.1007/978-0-387-72124-8_38. Adv Exp Med Biol. 2007. PMID: 17966437 Review.